Bone Denisty Change in Children With Beta Thalassemia Major

Sponsor
Marwa Hassan Abdelhamed Hassan (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06069089
Collaborator
Assiut University (Other)
42
12.6

Study Details

Study Description

Brief Summary

Bone denisty changes in children with beta thalassemia major

Condition or Disease Intervention/Treatment Phase
  • Radiation: Dexa scan

Detailed Description

Beta Thalassemia major (TM) is a hereditary disease caused by defective Beta globin chain synthesis, resulting in abnormal as well as a decreased quantity of globin chains, ineffective erythropoiesis, haemolysis and increased red blood cell turnover (Cooley, etal, 1927). described the first patient with anemia, splenomegaly, cranial & facial bone enlargement. Pathophysiology of bone denisity changes in beta thalassemia major Several studies had been previously evaluated; shown that multiple factors may act in concert to produce bone disease in beta thalassemia major (TM) including bone marrow expansion (Shamshirsaz, etal, 2003). hypogonadism (Anapliotou,Saka&Jensen,1998), defective growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis (Soliman,etal,1998), altered pattern of cytokines (Morabito,etal,2007), iron deposit in bone ((Bordat,etal,1993),deferoxamine bone toxicity (Chan ,etal, 2002),and vitamin D deficiency (Dandona, etal, 1987). Some of these pathogenic factors, directly and/or indirectly, affect osteoblastic population, leading to depressed bone formation, while others often increase osteoclastic bone resorption.

Complications of transfusion dependent poorly controlled beta thalassemia major are;(1)-Osteoprosis; Iron overload impairs osteoid maturation and inhibits local mineralization to form focal osteomalacia. In addition, integration of iron in calcium hydroxyapatite affects the growth of crystals, which causes mineralization failure (Chan, etal, 2002), defective growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis (Soliman, etal, 1998),altered pattern of cytokines (Morabito,etal, 2007), iron deposit in bone (Bordat, etal, 1993), deferoxamine bone toxicity (Chan, etal,2002). and vitamin D deficiency (Dandona, etal, 1987). (2)-Fractures; The introduction of red blood cell transfusion and concomitant iron chelation therapy has led to improved bone health through various mechanisms. It leads to a reduction in medullary expansion and cortical bone thinning, the reduced incidence of hypogonadism, and a reduction in other endocrine complications such as hypoparathyroidism and metabolic disorders that predispose to low bone density and fractures( Multicentre study, italian working group 1995). Z-score of bone density will be calculated. Z score is the preferred parameter in children. which is calculated as the number of standard deviations above or below the mean for the patient's age, sex,

Study Design

Study Type:
Observational
Anticipated Enrollment :
42 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Assiut University, Pediatrician Department
Anticipated Study Start Date :
Dec 15, 2023
Anticipated Primary Completion Date :
Dec 15, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Controlled beta thalassemia major

Controlled beta thalassemia major Hb>9g/dl , serum ferritin <500ng/ml

Radiation: Dexa scan
No intervention

Uncontrolled beta thalassemia major

Uncontrolled beta thalassemia major Hb<9g/dl , serum ferritin >500ng/ml

Radiation: Dexa scan
No intervention

Outcome Measures

Primary Outcome Measures

  1. Evaluate bone denisty in children with beta thalassemia major [One year]

    To evaluate bone denisty in transfusion dependent beta thalassemia major & its relation to serum minerals &vit D To evaluate bone denisity in transfusion dependent beta thalassemia major & its relation to serum minerals &vit D To evaluate bone denisity in transfusion dependent beta thalassemia major &its relation to serrum minerals &vitD

Eligibility Criteria

Criteria

Ages Eligible for Study:
10 Years to 18 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patient diagnosed as B thalassemia major of both sexes, age range from 10-18 year, who are poorly controlled on frequant blood transfusion. The patient who doesn't have Hb level from 9-10 g/dl, in almost always less than 9 g/dl.
Exclusion Criteria:
  • Known metabolic bone disease. Less than 10 year or more than 18 year. Bone disease Other than hemolytic anemia.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Marwa Hassan Abdelhamed Hassan
  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Marwa Hassan Abdelhamed Hassan, Assiut university , pediatrician department, Assiut University
ClinicalTrials.gov Identifier:
NCT06069089
Other Study ID Numbers:
  • Thalassemia major in children
First Posted:
Oct 5, 2023
Last Update Posted:
Oct 5, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 5, 2023